OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← Malaria No More United Kingdom

2024-12-31-accounts

January to December 2024

Welcome to Malaria No More UK’s Trustees Report 2024

Against a backdrop of political uncertainty and constrained funding, Malaria No More UK (MNMUK) has worked to ensure malaria stays a priority globally as well as nationally in both the UK and Kenya. Through our ongoing engagement with malaria partners, targeted advocacy and creative communications tactics, we’ve seen significant results:

We have deepened our engagement with the Commonwealth, a group of nations that are pivotal in galvanising both donor and endemic countries behind the malaria fight. This has led to the Commonwealth reaffirming its commitment to ending malaria and specifically calling for the successful replenishment of the Global Fund in 2025.

The UK committing over £10 million to malaria initiatives and committing to multi-year funding to Product Development Partnerships (PDPs) – a vital instrument for malaria.

The Commonwealth reaffirming its commitment to ending malaria in its communique from the Commonwealth Health Ministers Meeting and Commonwealth Heads of Government Meeting (CHOGM).

Partnerships have been the driving force behind all that Malaria No More UK has achieved.

We proudly announced His Majesty King Charles III’s role as MNMUK Royal Patron. The King’s commitment and leadership will undoubtedly amplify efforts to combat malaria in the Commonwealth and across the globe.

In the UK, during a General Election year and a shift to a new government, we focused our efforts on building relationships across parties and deepened our collaboration with malaria and broader civil society partners, resulting in increased investment from the UK government.

In Kenya, we worked with the National Malaria Control Programme, the Zero Malaria Campaign Coalition, media partners, young people and local leadership to launch the Power of EveryONE to build awareness and knowledge and shift attitudes and behaviours. So far, the campaign has reached 34 million people, with many of those reached committing to take action to end malaria.

In September, we celebrated the launch of a powerful new partnership with the African Leaders Malaria Alliance (ALMA). ALMA is instrumental in driving action and holding governments accountable, while MNMUK brings expertise in creative communications campaigns and targeted advocacy. Through a strengthened partnership, our joint engagements have centred on amplifying the voices of affected communities and strengthening the connection between African leaders and the global community of donors to the malaria fight.

The MNMUK team collaborated with malaria scientists, global health experts, campaigners, and Zero Malaria ambassadors, including David Beckham, to create the Zero Malaria Experience – a film and immersive installation that demonstrates how innovation and funding can save millions of children’s lives, highlighting the power of partnership in combating malaria.

Yet there is more to be done.

1

Contents

We are at a critical juncture in the fight to eradicate malaria. The latest World Malaria Report from the World Health Organisation paints a mixed picture of progress. While we are seeing reduced mortality and advancements in science and innovation, there is a significant risk that funding gaps will stall global efforts and put lives at risk. According to new modelling data prepared by the Malaria Atlas Project (MAP), if the Global Fund fails to secure increased funding, the world will be facing a malaria resurgence with as many as 300,000 additional lives lost. Any rise in the disease pushes us further away from any hope of ending malaria as an epidemic that kills almost half a million children a year.

We cannot let that happen. We must Change the Story. Decisions that will be taken in the months to come will determine the trajectory of the malaria fight and impact millions of lives. The team at MNMUK is determined to use its strategic campaigning skills and partnerships to ensure the right decisions are made.

On behalf of myself and the Board of Trustees at MNMUK, I would like to thank everyone who is part of our shared mission – the incredible and determined MNMUK staff, our fantastic ambassadors, and our vital partners, funders and supporters. Thank you for being an integral part of the fight to end malaria.

David Reddy Board Chair

2

WHO WE ARE

Our Vision A world without malaria in our lifetimes. Our Mission Our mission is to catalyse and inspire the global partnerships, leadership and financing to end malaria. OUR VALUES Collective Voice We believe that through the combined power of many voices, lived experiences and diverse perspectives, we will end malaria for good. Creativity We believe in the power of creative ideas. Drawing from diverse skills, experiences and cultures, we foster innovative thinking that will bring us closer to our vision of a malaria free world. an Ambition We will embody a brave, bold and determined spirit, challenging ourselves and others to aim for greater impact in the malaria fight. Inclusivity We are fully committed to the practices and behaviours that promote and uphold principles of equity, diversity and inclusion. i . Agility To be responsive to the needs of our communities and deliver impact in an ever-changing world, we actively listen, learn and adapt.

3

OUR APPROACH

We deliver strategic campaigning: the right message, to the right audience, at the right time. Through our unique mix of creative communications, bold political advocacy, powerful partnerships and sheer determination, we work to make the voices of those affected by malaria impossible to ignore.

Targeting messaging for key audiences Connecting our CAMPAIGNS THAT Amplifying advocates’ creative network to UNITE PARTNERS voices in malariaendemic countries the malaria fight AND SPARK ACTION “QO ag Utilising influential voices to reach across the globe

4

MALARIA IN 2024

597,000 LIVES reported lost in the 2024 World Malaria Report

17 COUNTRIES started rolling out new malaria vaccines

1 CHILD dying every minute from malaria

THE PATH TO ZERO

44 COUNTRIES and one territory certified malaria free

25 ENDEMIC COUNTRIES now reporting fewer than ten cases of malaria each year

16% REDUCTION in malaria mortality rate in the African region since 2015

5

Catherina 11 years old, Côte d’Ivoire

| “ Because I get malaria, I miss a lot of school, and I miss exams. If there was no malaria, everyone could reach their dreams and do what they want.

6

Building the case for ending malaria

Our work is driven by the urgent need to end malaria and its devastating impact, not only as a moral imperative but also as a vital investment in global health security and economic resilience. In a world where governments face competing budget priorities, in 2024 we continued to develop compelling messaging and arguments to help make the case for them to invest.

Fighting malaria offers a global economic boost

This year Malaria No More UK commissioned brand new research, carried out by Oxford Economics Africa, that revealed that getting back on track to the Sustainable Development Goal of cutting malaria by 90% by 2030, could boost the economies of malaria-endemic countries by an incredible $142.7 billion.

The report The Malaria Dividend: why investing in malaria innovation creates returns for all helped make the economic case for investment - : \ in malaria. Its findings supported direct advocacy and media coverage in G7 nations, and several malaria endemic countries. 4

KEY SUCCESSES

COVERED BY 66 DIFFERENT MEDIA OUTLETS ACROSS 13 COUNTRIES

OUR PARTNERS USED THE REPORT TO ADVOCATE FOR INVESTMENT IN FIGHTING MALARIA. USED BY THE UN TO ADVOCATE FOR MALARIA FUNDING IN GLOBAL GOVERNMENT BRIEFINGS, INCLUDING THE G7

GO TO THE REPORT

7

George Otieno Fisherman, Kenya

gs | gee omen sere “ Malaria is always affecting my family. When you are sick with malaria, it means you are not going to work. It’s important to advocate to end malaria so it can give us the energy to build our economy.

8

Championing UK commitment: the path to sustained support Malaria No More UK has a strong history of championing and encouraging UK support for the malaria fight. In 2024 we focussed on laying P| \ the groundwork for sustained contributions = ~ by the UK to the 2025 Global Fund and Gavi replenishments, and for continued investment = as in Product Development Partnerships (PDPs) Be oe ’ who help develop and expand access to malaria es peseetetnsesinuns>ii2so52-40~--s--_~2-..2727-2-2-by¢ innovations.

During a year in which a General Election saw a change in the governing political party, Malaria No More UK successfully engaged Parliamentarians, Ministers and their advisors from across the political spectrum, through events, reports and targeted media coverage. Following the general election, we helped reestablish the APPG for Malaria and Neglected Tropical Diseases.

Science and innovation saving lives

Never have such a powerful set of tools existed to fight malaria, from next generation mosquito nets and new treatments to two new malaria vaccines that are now being delivered to children across 17 countries in Africa.

In 2024 the life-saving power of science and innovation continued to be a golden 4 thread running through our advocacy and communications – from seeking out and profiling _ # examples of innovation from African based ; research institutions to showcasing the long history of achievement from UK-backed science. : '

Highlighting the power of “British Backed Science” through media and directly to Parliamentarians has been especially powerful as we work aH 4 2 - with PDPs to ensure the UK strengthens its ay support of malaria R&D. PDPs are central to the development of new vector control technologies and life-saving malaria treatments. By profiling é their innovative work we worked together to secure new commitments to multi-year funding from the UK.

KEY SUCCESSES

In January, the UK Government announced it would match the first £2 million of pledges from the private sector to Gavi, the Vaccine Alliance, and a further £10 million for research into effective malaria vaccine deployment. The year saw PDP partners able to access new multi-year funding from the UK for their work developing life-saving malaria prevention and treatment innovations.

9

Ugandan dance troupe The Ghetto Kids meet Lord Cameron In March, young malaria champions The Ghetto Kids joined Commonwealth Day celebrations in Westminster Abbey, aa after which we arranged a meeting } with UK Secretary of State for Foreign, Commonwealth and Development Affairs, ait iy The Rt Hon Lord Cameron. The Ghetto Kids were able to share why a Zero Malaria world is important to them from personal experience.

10

WATCH THE FILM

“ , 7 a 687 million digital impressions " ‘4 3.7 million ie ‘s ‘ y A “ts ' F 2 people reached through out-of-home engagement aati a 4 ‘es ; , wit G ar Sy ao J Cae 2, , yA s ee tt ’ 925,000 4 f ’ ’ : al ——— people reached through ; media articles

The Zero Malaria Experience: * How innovation and funding can save children’s lives

As Gavi and the Global Fund approach critical ~~ replenishments, keeping malaria on the global political agenda has been more important than ever. In a powerful film, Zero Malaria ambassador * a. and MNMUK Leadership Council member David Beckham joins malaria scientists, global health 4 o> 4 experts, campaigners, and leaders to highlight ‘es the lifesaving potential of existing and new malaria-fighting tools.[‘] e ‘ © s

, Research from Imperial College London ® bs ad - . estimates that – if malaria fighting tools ; “9 _— reached those who need them – « bl 13.2 million 7 4 lives could be saved over the next 15 years in , ‘ Sy +7 sub-Saharan Africa. er a>) i + oe That’s 900,000 lives a year. > Neg

With support from renowned creative agency The Mill, the research and film were the basis of : toa ‘ i an immersive installation and event at London’s Outernet. The “Zero Malaria Experience” (ZMX) was developed for the malaria community, to deploy at key moments, bringing together a broad range of malaria partners and representing the multiple tools, geographies and individuals that need to work together to combat malaria.

ZMX provided a platform for Gavi and the Global Fund to demonstrate their vital role in reaching communities at risk from malaria. Both organisations were featured in the film and spoke at the launch event, allowing the two replenishments to be discussed together on a public stage. With over 47 organisations participating in the launch, the film and event united voices across the malaria community, showcasing the unified strength of one collective voice, calling for action to end malaria for good.

12

Celebrating the Power of EveryONE to end malaria in Kenya a

In February 2024 we and the Zero Malaria Campaign Coalition launched the Zero Malaria Starts with Me: The Power of EveryONE , a campaign developed in collaboration with partners in Kenya including the National Malaria Control Program. It shows the opportunity every Kenyan has, to help end malaria and is distinctive as it features community malaria champions as its heroes.

A national launch saw The Power of EveryONE featured in media and on billboards across Kenya – highlighting the chance to end malaria nationwide. Two months later it featured as part of the country’s World Malaria Day activity.

The Power of EveryONE also drove awareness in three target counties where people are living at particular risk from malaria — Kilifi, Kakamega, and Kisumu. We supported partners to deliver social behaviour change communications (SBCC) , encouraging correct use of insecticide treated mosquito nets, care-seeking when sick and SHAN WA AFYAYA prevention of malaria during pregnancy. (ARIBUNAWE

We trained campaign spokespeople to appear in county media while radio stations ran Power of EveryONE adverts, recorded in local languages. As community champions appeared in billboards and posters, we supported our partners the Kenya Malaria Youth Corps to deliver SBCC events designed to deepen malaria understanding amongst groups such as boda boda riders, fishing communities and young mothers.

os Early indications suggest community members taking part are ready to make a difference. 98% of those attending a Power of EveryONE SBCC event said they would speak to family, friends and loved ones about malaria (an increase from 40% in an earlier study), showing — = how the campaign is helping change lives, one > an conversation at a time.

13

34 million people reached by the campaign

DISCOVER MORE

40 trained community spokespeople

25 media outlets engaged = ~~"~~ ,

Eunice Adhiambo Serine. $

“ , Malaria is deadly, but now ; I know how to prevent it. Knowledge is power.

Eunice works on the shores of Lake Victoria, selling fish at her small hotel at Dunga Beach. When attending a Power of EveryONE discussion group, Eunice and her fellow attendees were taught that mosquitoes bring malaria to their communities. The session broke myths and gave Eunice tools to fight back - by using insecticide treated bed nets, keeping the environment fs clean, and seeking proper medical care.

The sessions gave Eunice the confidence to advocate for malaria prevention, urging others to see a doctor, use mosquito nets, and protect themselves. Her commitment deepened after her seven-year-old daughter’s contracted malaria; she thankfully made a full recovery. Now, Eunice educates her community, including fishermen, turning her experience into action to help others stay safe and healthy. For Eunice, malaria isn’t just a part of life, it’s a battle that can be won. “Malaria is deadly,” she says simply. “But now I know how to prevent it. Knowledge is power.”

15

Change the Story: Raising voices in the fight against malaria

Launched in 2023 ‘Zero Malaria: Change the Story’ set out to amplify the voices of children affected by malaria while spotlighting the growing threats to malaria elimination including extreme weather events, insecticide resistance and drug resistance.

Recognising the campaign’s impact, the World Health Organization (WHO) commissioned us to create Zero Malaria: Ghetto Kids X Change The Story, a powerful film for the Malaria Ministerial Bi High Burden High Impact (HBHI) Conference in Yaoundé, Cameroon. At the conference health ministers signed the Yaoundé Declaration, a pledge by the 11 countries with the highest malaria burden to accelerate action against malaria deaths.

To mark World Malaria Day 2024, we created another compelling Change The Story film, shedding light on the devastating impact of malaria on women and girls. The film calls on global leaders to champion their leadership and empowerment as a means to drive lasting —) change.

These films gained significant traction, and were shared by David Beckham, The Ghetto Kids, Eliud jeeet Kipchoge, Anyika Onuora, Charlie Webster and re Faith Kipyegon, as well as the WHO. Their reach extended to tens of millions of people worldwide, keeping malaria at the forefront of the global agenda and reinforcing the urgency of action.

Building on this momentum, the WHO commissioned two additional Change The Story films to coincide with the launch of the 2024 World Malaria Report (WMR). These films explored the human toll of malaria, highlighting female empowerment, vaccines and next generation bed nets. Featured prominently on WHO’s World Malaria Report homepage and social media channels, the films achieved a combined potential reach of 12 million - with one film alone having been watched for the equivalent of 6 days.

WATCH THE FILM D744 =

16

Looking ahead

Global financing for malaria programming is facing multiple challenges, the likes of which haven’t been seen since the inception of the Global Fund more than two decades ago.

Malaria No More UK remains focused on this year’s Global Fund replenishment while also supporting efforts to bring in new finance. We are more determined than ever to play a key role in leveraging our connections and technical expertise to capture the stories from malaria endemic countries and amplify these with decisionmakers at a global level. We will continue to deliver targeted, audience-specific support that maximises impact, working in partnership and solidarity with critical partners across the malaria community.

We know that by bringing diverse people, voices, ideas and action together, we can end malaria and save millions of lives.

17

MALARIA TODAY

MALARIANOMORE.ORG.UK

@MALARIANOMOREUK

COMPANY NUMBER 06648679

CHARITY NUMBER 1126222

REGISTERED IN ENGLAND AND WALES

85 GREAT PORTLAND STREET, FIRST FLOOR, LONDON, W1W 7LT

DIRECTORS REPORT AND ACCOUNTS 21

KEY INFORMATION

Leadership Council:

Founding Patrons:

Global Patrons:

WITH THANKS

We are not in this alone; MNMUK is grateful to all our donors, supporters and partners, including those who provide pro bono support and those who prefer to remain anonymous.

You are helping bring an end to Malaria.

Funders:

Partners donating resources, talent and time

22

==> picture [36 x 188] intentionally omitted <==

The Trustees are pleased to present their report together with the audited financial statements of the Charity for the year to 31 December 2024. The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity’s Memorandum and Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice ‘Accounting and Reporting by Charities’ (revised 2015).

Structure, governance and management governing document

Malaria No More United Kingdom is a charitable company limited by guarantee, incorporated on 16 July 2008 and registered as a Charity on 8 October 2008. The company is governed by its Memorandum and Articles of Association.

Directors

The directors of the charitable company are its Trustees for the purpose of Charity law, and the members of the company limited by guarantee. Throughout this report, they are collectively referred to as the Trustees.

The following individuals served as Trustees during the year:

All Trustees served for the full year unless otherwise stated above.

No Trustees had any beneficial interest in the Charity, and no Trustee is paid remuneration by the Charity.

The Board of Trustees is responsible for the Charity’s strategic direction, policy and governance.

The implementation of the strategy, once agreed, and the day-to-day running and management of the Charity’s activities are delegated to the secretariat, led by the Managing Director.

23

Risk management

The Trustees regularly review the Charity’s risks and are satisfied that relevant systems are in place to mitigate their exposure to major risks. The Charity maintains a risk register that is updated quarterly. The top four risks are:

All risks have mitigation strategies and monitoring actions identified and are reviewed and updated regularly.

MNMUK maintains a risk register that the leadership team updates and reviews regularly. The Audit and Risk Committee is mandated to review the risk register and provide feedback and guidance to the Trustees. The Committee met five times in 2024.

MNMUK has a Crisis Management Team led by the Managing Director, which meets at least once every quarter.

Public benefit

The Trustees confirm that they have complied with their duty under Section 17 (5) of the Charities Act 2011 to have due regard to the Charity Commission’s general guidance on public benefit.

Senior executive remuneration

Salaries for permanent staff across all functions have been set in line with market rate indicators and internal parity. Any salary adjustments made in the year are aligned with the organisation’s policy on salary banding.

The Charity publishes the salaries of its key management personnel in its annual report. The number of staff paid over £60,000 is also published in accordance with the Charity accounting requirements.

24

==> picture [36 x 188] intentionally omitted <==

Structure, governance and management

Malaria No More UK is a registered Charity and a company limited by guarantee without share capital and is governed by its memorandum and articles of association. The group includes a wholly owned subsidiary company, Malaria No More Trading, through which its’ cause marketing’ activities are carried out.

The Charity is governed by the Board of Trustees. The Board operates a quarterly meeting cycle, with an Audit and Risk Committee meeting before the main Board meeting. The Board, with the Executive Directors, reviews progress against the organisation’s strategic aims, governance and structure, and consideration of the changing external environment. The retail operations were governed separately by the Malaria No More Trading director.

Fundraising practices

As part of MNMUK’s commitment to best practice, the Charity is registered with the Fundraising Regulator and is committed to delivering its fundraising in a legal, honest and open way and in line with the Fundraising Codes of Practice.

The Charity has several clearly documented policies and procedures, including a complaints policy, which enables any concerns from the public regarding MNMUK’s fundraising practices to be heard and addressed in a timely manner. During the year, no complaints were received from the general public. There have also been no instances of non-compliance with the Fundraising Code of Practice requirements.

Equity, Diversity and Inclusion

MNMUK’s Equality, Diversity and Inclusion Strategy guides the organisation to ensure our work does not produce, reproduce or sustain the inequalities, exclusions and oppressions that we seek to address in the fight to end malaria. Beyond this, our ambition through our EDI strategy is to embed a social justice approach to the work that we do and the malaria fight, and centre EDI principles in how we are led and how we advocate and influence both internally and externally.

Investment policy and performance

MNMUK invests funds which exceed working capital requirements, to preserve the real value of capital, as well as for income generation.

At the end of 2023, the investments were held in a mixture of equities, bonds, cash and other investments and were managed by Rathbones. This arrangement ceased during 2024, and the funds were allocated to shorter term investments.

25

Financial review

The consolidated accounts for the year are set out on pages -- to -- and should be read with this section of the Trustees’ Report. A summary of the financial results and the work of the Charity is set out below.

The net movement in funds for the year totalled £ 198,000. This is made up of
Incoming resources
Resources expended

Net outgoing resources
Net gains / (losses) on investments
Net movement in funds		 £4,218,636
(£4,083, 788)
£134,848
£63,385
£198,233

During 2024, MNMUK continued to receive support from its longstanding partner, the Gates Foundation. The third payment of the three-year grant (2022-2025) - “Unlocking the Path to Eradication”- was received in July 2024. This contribution is central to supporting MNMUK’s work to help catalyse the political commitment, financing, and collective action needed to reach international malaria reduction targets and establish a pathway to achieving malaria elimination. A grant renewal process for another two years of funding is underway, and the Charity is confident that it will receive the necessary approvals by the end of September 2025.

As MNMUK continued to deliver Africa-focused advocacy and communications, including the Zero Malaria Campaign Coalition in Kenya and the continued development and delivery of Zero Malaria brand communications, e.g. the Power of Everyone” campaign, funding support was deployed and received from various donors, including long-term supporters, Fever-Tree.

Open Philanthropy awarded MNMUK an additional closing-off grant of £234k in 2024; the funds will continue to support work on advocacy for malaria funding from donor governments and organisational strengthening.

Funding was received from Medicines for Malaria Venture and pharmaceutical company GSK to support specific areas of MNMUK’s work.

As hosts of the All-Party Parliamentary Group (APPG) secretariat for Malaria and NTDs, MNMUK received £73k in restricted funding from APPG supporters.

26

2024 income compared with 2023

==> picture [533 x 263] intentionally omitted <==

----- Start of picture text -----
5,000,000
4,500,000
4,000,000
3,500,000
£
3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
Donations and Donations - Charitable Other trading Investments Total (without Total
legacies Gift in Kind activities activities and others Gift in Kind)
2024 £ 209,876 - £ 3,834,115 £ 100,000 £ 138,030 £ 4,282,021 £ 4,282,021
2023 £ 354,025 £ 319,000 £ 3,887,441 £ 100,000 £ 75,237 £ 4,416,703 £ 4,735,703
% Change -41% -100% -1% 0% 83% -3% -10%
----- End of picture text -----

The total incoming resources, including investment gains, in 2024 totalled £4.282m, a 10% (£454k) decrease compared to 2023 income. Due to a change in accounting policy, donated services are not included in the 2024 accounts; excluding gift-in-kind income from 2023, the decrease in income is 3% (£135k).

MNMUK receives only limited income in the form of donations and fundraising from members of the public. In 2024, £75,520 was received through public fundraising activities, which included £2,492 received through the HMRC Gift Aid scheme; no legacy income was received in 2024, but £10,000 of legacy income was written off as the amount recoverable reduced. The breakdown of donations and legacy income for 2024 and 2023 is shown below.

Donations and legacies income breakdown 2024 2023 %Change
Public fundraising £75,520 £81,807 -8%
Gift aid £2,492 £2,698 -8%
Legacy (£10,000) £125,752 -108%
Donated services - £319,000 -100%
Corporate and other donations £141,864 £143,768 -1%
£209,876 £673,025 -69%

Trading income of £100k was received in 2024 from Fever-Tree; the same amount as was received in 2023 to support critical community campaigns in Kenya.

27

Bank interest plus gain on investment of £138k is 83% higher than the 2023 amount of £75k due to the increases in the Bank of England’s official base rate.

2024 expenditure compared with 2023

==> picture [533 x 225] intentionally omitted <==

----- Start of picture text -----
5,000,000
4,000,000
£
3,000,000
2,000,000
1,000,000
Raising funds Direct project Support costs Total
2024 £321,687 £2,953,804 £808,297 £4,083,788
2023 £104,876 £3,562,503 £1,112,783 £4,780,162
----- End of picture text -----

To offset the decline in income, management acted to reduce costs where possible without affecting the quality of services provided to partners while still ensuring efficient and effective use of resources received from our funders. The overall reduction in expenditure was 15% from £4.8m in 2023 to £4.1m in 2024.

72% of total expenditure was spent on direct charitable activities (2023: 75%). Spending on support was reduced by 27% from £1.1m to £808k by reducing administration and office management costs.

The cost reductions helped strengthen the Charity’s Balance Sheet in 2024, with net assets rising by 10% to £2,160,664 compared to £1,962,431 in 2023. Restricted funds amounted to £1,055,943 compared to £1,030,445 in 2023. The total cash in hand available to the Charity decreased by £599,503 from £2,287,406 to £1,687,903 in 2024. This decrease is mainly due to a reduction in grant income received in advance in 2024.

2024 expenditure breakdown

==> picture [325 x 123] intentionally omitted <==

----- Start of picture text -----
Support costs
808,297 (20%)
Raising funds
Direct project 321,687 (8%)
2,953,804 (72%)
----- End of picture text -----

Reserves

The Trustees’ policy, updated in November 2022, is to maintain two reserves, together shown on the balance sheet as unrestricted funds: one, equivalent to the value of four months’ core operating costs (The Resilience Reserve), and two, reserves allocated to specific future projects to be delivered within 24 months (The Designated Reserves).

==> picture [483 x 139] intentionally omitted <==

----- Start of picture text -----
Reserves level
Target level £1,002,916 £501,458
Actual level £1,002,916 £101,806
----- End of picture text -----

Resilience reserves - 4 months Core Cost Designated reserves - Extra 2 months Core Cost

The resilience reserve based on planned fixed expenditure for 2025 is £1,002,916, while the designated reserve is £501,458.

At the end of 2024, the unrestricted reserves amounted to £1,104,722, which is the year’s full Resilience Reserve, and 20% (£101,806) of the required designated reserves to carry forward to 2025.

28

Responsibilities of trustees in relation to the financial statements

The Trustees (also the Directors of Malaria No More UK) are responsible for preparing the Report of the Trustees and the financial statements per applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the charitable company’s state of affairs and the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the Trustees are required to:

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the Trustees are aware:

This report was approved by the Board of Trustees on 19th September 2025 and signed on its behalf by:

______ ______ Stewart Forster Cox, Treasurer David Reddy, Interim Board Chair

Company registration number: 06648679

Consolidated statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 December 2024

r ended 31 December 2024 r ended 31 December 2024
tween funds
Unrestricted
Note
£
m
:
2
45,386
3
4
100,000
74,645
-
220,031
5
79,384
258,561
337,945
32,089
6
17
(85,825)
172,736
o
n
o
f
f
u
n
d
s
:
931,986
1,104,722


e
e
o
n
:
nd legacies
ctivities
g activities
s
/ (expenditure) for the year
258,561

d
i
t
u
r
e
/
(
e
x
p
e
n
d
i
t
u
r
e
)
b
e
f
o
r
e
n
e
t
g
a
i
n
s
/
i
n
v
e
s
t
m
e
n
t
s
ctivities
osses) on investments
(117,914)
brought forward
c
a
r
r
i
e
d
f
o
r
w
a
r
d
e
n
t
i
n
f
u
n
d
s		 Restricted
£
164,490
3,834,115
-
-
-		 2024

 Unrestricted
£
529,257
100,000
15,981
44		 Restricted
£
143,768
3,887,441
-
40,000
-		 2023
T
o
t
a
l
£
209,876
3,834,115
100.000
74,645
-		 Total
£
673,025
3,887,441
100,000
55,981
44
220,031 3,998,605 4,218,636 645,282 4,071,209 4,716,491
79,384
258,561		 3,424,156
321,687		 401,071
3,682,717		 216,154
662,458		 3,901,549 216,154
4,564,007
337,945 3,745,843 4,083,788 878,612 3,901,549 4,780,161
32,089
(117,914)		 31,296
252,762		 63,385
134,848		 19,212
(233,330)		 ~~-~~
169,660		 19,212
(63,670)
(85,825)
258,561		 284,059
(258,561)		 198,233
-		 (214,118)
-		 169,660
-		 (44,458)
-
172,736
931,986		 25,498
1,030,445		 198,233
1,962,431		 (214,118)
1,146,104		 169,660
860,785		 (44,458)
2,006,889
1,104,722 1,055,943 2,160,664 931,986 1,030,445 1,962,431
ve results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movem
closed in Note 18a to the fnancial statements.		 ents in

33

Balance sheet

Balance sheet
Balance sheet Company registration number: 06648679 Company registration number: 06648679 Company registration number: 06648679
As at 31 December 2024 As at 31 December 2024
The group The charity The charity
2024 2023 2024 2023
Note £
£		 £
£		 £
£		 £
F
i
x
e
d
a
s
s
e
t
s
:
Fixed assets:
Tangible assets 9 10,461 15,447 10,461 15,447
Investments 17 501,173 1,544,457 501,173 1,544,457
511,634 1,559,904 511,634 1,559,904
C
u
r
r
e
n
t
a
s
s
e
t
s
:
Current assets:
Debtors 12 126,939 253,225 126,348 318,639
Cash at bank and in hand Cash at bank and in hand 1,687,903 2,287,406 1,686,114 2,154,718
1,814,842 2,540,631 1,812,462 2,473,357
L
i
a
b
i
l
i
t
i
e
s
:
Liabilities:
Creditors: Deferred income 14 - (1,754,546) - (1,754,546)
Creditors: amounts falling due within one year 13 (165,812) (383,558) (236,299) (382,983)
(165,812) (2,138,104) (236,299) (2,137,529)
N
e
t
c
u
r
r
e
n
t
a
s
s
e
t
s
Net current assets		 1,649,030 402,527 1,576,163 335,828
T
o
t
a
l
a
s
s
e
t
s
l
e
s
s
Total assets less		 c
u
r
r
e
n
t
l
current		 l
i
a
b
i
l
i
t
i
e
s
liabilities		 2,160,664 1,962,431 2,087,797 1,895,732
F
u
n
d
s
:
Funds:		 18a
Unrestricted income funds Unrestricted income funds 1,104,722 931,986 1,031,855 865,287
Resilience reserve 1,002,916 931,986 1,002,916 865,287
Designated reserve 101,806 - 28,939 -
Total unrestricted funds 1,104,722 931,986 1,031,855 865,287
Restricted income funds 1,055,943 1,030,445 1,055,943 1,030,445
T
o
t
a
l
f
u
n
d
s
Total funds		 2,160,664 1,962,431 2,087,798 1,895,732

Approved by the Board of Trustees on 19th September 2025 and signed on its behalf by:

David Reddy, Interim Board Chair

34

Company registration number: 06648679

Consolidated statement of cash flows

For the year ended 31 December 2024
Note
Net income / (expenditure) for the reporting period
(as per the statement of fnancial activities)
Depreciation charges
(Gains)/losses on investments
Dividends, interest and rent from investments
Decrease / (increase) in debtors
Decrease / (increase) in creditors
Increase/(decrease) in deferred income
Net cash (used in) /provided by operating activities
Net cash (used in) /provided by investing activities
Cash and cash equivalents at the beginning of the year
C
a
s
h
a
n
d
c
a
s
h
e
q
u
i
v
a
l
e
n
t
s
a
t
t
h
e
e
n
d
o
f
t
h
e
y
e
a
r
C
h
a
n
g
e
i
n
c
a
s
h
a
n
d
c
a
s
h
e
q
u
i
v
a
l
e
n
t
s
i
n
t
h
e
y
e
a
r
C
a
s
h
f
l
o
w
s
f
r
o
m
o
p
e
r
a
t
i
n
g
a
c
t
i
v
i
t
i
e
s
C
a
s
h
f
l
o
w
s
f
r
o
m
i
n
v
e
s
t
i
n
g
a
c
t
i
v
i
t
i
e
s
:
Dividends, interest and rents from investments
Purchase of fxed assets
Proceeds from sale of investments
Purchase of investments		 2024
£
£
198,233
10,623
(63,385)
(74,645)
126,286
(1,754,546)
(217,746)
74,645
(5,637)
2,106,669
(1,000,000)
1,175,676
(599,503)
2,287,406
1,687,903
(1,775,179)
2023
£
198,233
10,623
(63,385)
(74,645)
126,286
(1,754,546)
(217,746)
74,645
(5,637)
2,106,669
(1,000,000)		 £
(44,458)
13,713
(19,212)
(55,981)
19,888
143,208
(1,509,369)
55,981
(16,355)
1,000,000
(2,022,675)		 £
1,175,676
(1,775,179)		 (1,452,211)
(983,048)
(599,503)
2,287,406		 (2,435,259)
4,722,665
1,687,903 2,287,406

35

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

Some long-standing funding streams will be ending in 2025. In response, the charity has continued to implement its strategy of income diversification and cost reduction to ensure it remains aligned with its objectives. As part of this, scenario planning was undertaken to identify financially viable models under various future funding conditions.

regarding the charity’s ability to continue as a going concern.

e) Income All incoming resources are included In the statement of financial activities when the charity Is entitled to the income and the amount can be quantifed with reasonable accuracy. The followlng specific policies are applied to particular categories of Income.

f) Fund accounting

g ) Ex penditure and irrecoverable VAT

Expenditure is recognised on an accruals basis as a liability is incurred, and includes any VAT which cannot be fully recovered.

h) Operating leases Rental costs are charged on a straight line basis over the term of the lease.

36

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

i) Tang ible fix ed assets

provided at rates calculated to write off the cost on a straight line basis over their expected useful economic life. The rate of depreciation is 33.33% per annum for all assets.

k) Debtors Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l) Cash at bank and in hand Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) Creditors and provisions

n) Deferred income

Income is deferred by the charity only if there is a donor-imposed condition or restraint preventing the recogntiion of restricted income in the SoFA. This is in line with the charity's income recognition policy.

o) Financial instruments

instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 Income from donations and leg acies

ices Unrestricted
£
45,386
-		 £
164,490
-
Restricted		 2024
209,876
-
T
o
t
a
l
£		 Unrestricted

£
210,257
319,000
529,257		 £
143,768
-
Restricted		 2023
Total
£
354,025
319,000
45,386 164,490 209,876 143,768 673,025

Donated services represent pro bono time of numerous celebrities, legal and catering services and communications and PR support from several agencies. A change in income recognition policy in 2024 means donated service is no longer monetised in the financial statement as the amount that can be recognised did not fully reflect the invaluable time and resources received from our supporters.

3 Income from charitable activities

Grants

I
n
c
o
m
e
f
r
o
m
o
t
h
e
r
t
r
a
d
i
n
g
a
c
t
i
v
i
t
i
e
s
Cause related marketing		 Unrestricted
£
-		 £
3,834,115
Restricted		 2024
3,834,115
T
o
t
a
l
£		 Unrestricted

£
-

Unrestricted

£
100,000		 £
3,887,441
Restricted		 2023
Total
£
3,887,441
Unrestricted
£
100,000		 -
£
Restricted		 2024
100,000
T
o
t
a
l
£		 -
£
Restricted		 2023
Total
£
100,000

37

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

5a Analysis of ex penditure (current year)

Charitable activities

==> picture [490 x 218] intentionally omitted <==

----- Start of picture text -----
Global
UK Campaign Campaign
Raising funds and Activities and Activities Governance Support costs 202 4 Total 2023 Total
£ £ £ £ £ £ £
Staff costs (Note 7) 302,580 1,003,675 771,750 - 416,599 2,494,604 2,152,552
Direct project costs - 380,316 798,063 - - 1,178,379 1,808,792
HR, recruitment and training - - - - 80,696 80,696 136,481
Legal and professional - - - - 8,943 8,943 8,286
Premises - - - - 156,896 156,896 211,547
Office running costs - - - - 116,386 116,386 144,943
Audit - - - 19,912 - 19,912 13,800
Consultancy costs - - - - - - 70,297
Strategic Development costs - - - - - - 86,301
Other costs - - - - 8,865 8,865 120,709
Fundraising costs 19,107 - - - - 19,107 26,453
321,687 1,383,991 1,569,813 19,912 788,385 4,083,788 4,780,161
Support costs 77,428 333,116 377,842 - (788,385)
Governance costs 1,956 8,414 9,543 (19,912) -
Total ex penditure 202 4 401,071 1,725,521 1,957,198 - - 4,083,788
Total expenditure 2023 216,154 1,926,182 2,637,825 - - 4,780,161
----- End of picture text -----

38

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

5 b Analysis of ex penditure (current year)

Charitable activities

==> picture [430 x 222] intentionally omitted <==

----- Start of picture text -----
Global
UK Campaign Campaign
Raising funds and Activities and Activities Governance Support costs 2023 Total
£ £ £ £ £ £
Staff costs (Note 7) 78,423 960,195 793,516 16,021 304,397 2,152,552
Direct project costs - 507,529 1,301,262 - 1,808,792
HR, recruitment and training - - - 13,648 122,833 136,482
Legal and professional - - - - 8,286 8,286
Premises - - - - 211,547 211,547
Office running costs - - - - 144,943 144,943
Audit - - - 13,800 13,800
Consultancy costs 70,297 70,297
Strategic Development costs 86,301 86,301
Other costs - - - 21,211 99,498 120,709
Fundraising costs 26,453 - - - - 26,453
104,876 1,467,724 2,094,778 64,680 1,048,103 4,780,162
Support costs 104,810 431,811 511,482 (1,048,103)
Governance costs 6,468 26,648 31,564 (64,680)
Total ex penditure 2023 216,154 1,926,183 2,637,825 - - 4,780,162
- - - - -
Total expenditure 2022
----- End of picture text -----

39

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

This is stated after charging / (crediting):

This is stated after charging / (crediting):
2024 2023
£ £
Depreciation 10,623 13,713
Operating lease rentals:
Property 145,553 195,
945
Auditor's remuneration (excluding VAT):
Audit 13,600 11,500
2024
£
2,071,437
199,779
223,387
2024
No.
34
35
2024
£
6
5
5
2
1
2,494,604
ion
average number of full-time equivalent employees during the period was
number of staf whose emoluments were in excess of £60,000 during the year were as follows:
l security costs
001 - £70,000
001 - £80,000
001 - £90000
001 - £100,000
average number of staf (headcount basis) during the period was
,001 - £120,000
ies and wages		 2024
£
2,071,437
199,779
223,387		 2023
£
1,
89,970
170,224
192,358
2,494,604 2,152,552
2023
No.
30
33
2023
No.
4
4
3
-
1

management personnel were £597,961(2023: £527,374).

The charity did not pay to its trustees any remuneration during the year (2023: £nil) or any reimbursed trustee expenses (2023: £nil).

8 Tax ation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

40

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

9 Tangible fix ed assets ~~-~~ charity and group

d on disposal
d of the year
d of the year
rt of the year
r the year
rt of the year
in year
t
i
o
n

v
a
l
u
e
in year

d
o
f
t
h
e
y
e
a
r
rt of the year
above assets are used for charitable purposes.		 Computer
equipment
£
74,428
5,637
-		 T
o
t
a
l
£
74,428
5,637
-
80,065 80,065
58,981
10,623
-		 58,981
10,623
-
69,604 69,604
10,461 10,461
15,447 15,447

10 Subsidiary undertaking

The Consolidated Statement of Financial Activities includes the results of the charity and its wholly owned subsidary Malaria No More UK Trading Limited, which conducts trading and merchandising activities on behalf of the charity. The company pays all of its profits to the charity by a gift aid donation. Malaria No More UK Trading Limited is registered under company number 07621448 and it's registered office is at Millbank Tower, 21-24 Millbank, London, SW1P 4QP.

A summary of the results of the subsidiary is shown below:

gate of the assets, liabilities and reserves was:
les & administrative expenses
a
i
n
e
d
e
a
r
n
i
n
g
s
c
a
r
r
i
e
d
f
o
r
w
a
r
d
e
a
r
n
i
n
g
s
o
f
i
t
ined earnings brought forward
s for the fnancial year
on under Gift Aid to parent charity		 2024
£
100,000
(27,134)		 2023
£
100,000
(
33,302)
72,866
66,699
72,866
(66,699)		 66,698
73,059
66,698
(73,059)
72,866 66,698
2,380
70,487		 132,688
(65,989)
72,867 66,699

11 Parent charity

The parent charity's gross income and the results for the year are disclosed as follows:

2024 2023
£ £
Gross income 4,197,421 4,669,004
Result for the year 125,366 (111,733)

41

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

Amounts due from group undertakings



3
Rent deposit
C
r
e
d
i
t
o
r
s
:
a
m
o
u
n
t
s
f
a
l
l
i
n
g
d
u
e
w
i
t
h
i
n
o
n
e
y
e
a
r
Sundry creditors and accruals
Trade creditors
Accrued income
Trade debtors
Other debtors
Deferred income
Inter group debtor
Prepayments
Accrued income
Amounts due from associated undertakings

e


o
r
s		 The group
2023
£
125,353
32,177
-
95,695
2024
£
3,130
34,542
47,445
11,376
253,225
126,939
-
-
2023
£
241,452
1,754,546
142,106
2024
£
44,821
-
120,991
2,138,104
165,812
-
-
-
-
30,446
-
-
-
The group		 The group
2023
£
125,353
32,177
-
95,695
2024
£
3,130
34,542
47,445
11,376
253,225
126,939
-
-
2023
£
241,452
1,754,546
142,106
2024
£
44,821
-
120,991
2,138,104
165,812
-
-
-
-
30,446
-
-
-
The group		 The charity The charity
2023
£
125,353
32,177
-
95,695
-
-
-
-
-		 2024
£
2,540
34,542
47,445
11,376
-
-
30,446
-
-		 2023
£
125,353
65,414
32,177
-
95,695
-
-
-
-
253,225 126,348 318,639
The charity
2023
£
241,452
1,754,546
142,106		 2024
£
42,265
-
194,034		 2023
£
240,762
1,754,546
142,221
2,138,104 236,299 2,137,529

14 Deferred income

in the year. The deferred balance is expected to be utilised over the 2023 financial year in line with the grant agreement.

The group The group The charity
2024 2023 2024 2023
£ £ £ £
Balance at the beginning of the year 1,754,546 3,263,915 1,754,546 3,263,915
Amount released to income in the year (1,754,546) (4,036,590) (1,754,546) (4,036,590)
Deferred income received in the year - 2,527,221 - 2,527,221
Balance at the end of the year - 1,754,546 - 1,754,546

15 Pension scheme

employer's contribution in additon to any personal contribution made by the staff themselves. The charity also allows staff who have "opted out" of the auto-enrolment scheme to nominate a personal pension plan to receive their pension contribution.

Pension costs stated in note 9 and charged in the Statement of Financial Activities represent the total contributions payable by the charity in the year.

16a Analysis of group net assets between funds (current year)

==> picture [474 x 90] intentionally omitted <==

----- Start of picture text -----
General
unrestricted Restricted funds Total funds
£ £ £
Tangible fixed assets 10,461 - 10,461
Investments 501,173 - 501,173
Current assets 613,000 1,201,843 1,814,842
Current liabilities (19,912) (145,900) (165,812)
Net assets at 31 December 202 4 1,104,722 1,055,943 2,160,664
----- End of picture text -----

42

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

16b Analysis of group net assets between funds (prior year)

==> picture [477 x 91] intentionally omitted <==

----- Start of picture text -----
General
unrestricted Restricted funds Total funds
£ £ £
Tangible fixed assets 15,447 - 15,447
Investments 1,060,240 484,217 1,544,457
Current assets 239,856 2,300,774 2,540,630
Current liabilities (383,558) (1,754,546) (2,138,104)
Net assets at 31 December 202 3 931,985 1,030,445 1,962,430
----- End of picture text -----

s
t
e


n
v
e
s
t
m
e
n
t
s
Fair value at the start of the year
Additions at cost
Disposal proceeds
Net gain / (loss) on change in fair value
Fair value at the end of the year
Investments comprise:
UK Common investment funds
Cash		 The group The group The charity The charity
2024
£
1,544,457
1,000,000
(2,106,669)
63,385		 2023
£
502,571
2,022,674
(1,000,000)
19,212		 2024
£
1,544,457
1,000,000
(2,106,669)
63,385		 2023
£
502,570
2,022,675
(1,000,000)
19,212
501,173 1,544,457 501,173 1,544,457
The group The charity
2024
£
501,082
91		 2023
£
1,544,061
396		 2024
£
501,082
91		 2023
£
1,544,061
396
501,173 1,544,457 501,173 1,544,457

18a Movements in funds (current year)

==> picture [478 x 196] intentionally omitted <==

----- Start of picture text -----
At 1 January Income & Expenditure At 31 December
2024 gains & losses Transfers 2024
£ £ £ £ £
Restricted funds:
The Gates Foundation 468,258 2,383,726 (2,244,964) (173,823) 433,197
All-party parliamentary group 73,093 29,500 (60,509) - 42,084
Open Philanthropy 421,223 1,485,647 (1,258,406) (84,738) 563,726
RES Africa 67,871 (3,961) (63,910) - -
Medicines for Malaria Venture - 47,490 (33,054) - 14,436
GlaxoSmithKline plc - 85,000 (85,000) - -
- 2,500 - - 2,500
Total restricted funds 1,030,445 4,029,902 (3,745,843) (258,561) 1,055,943
Unrestricted funds: 931,986 252,120 (337,945) 258,561 1,104,722
General funds 931,986 252,120 (337,945) 156,755 1,002,916
Designated reserve - - - 101,806 101,806
Total funds 1,962,431 4,282,021 (4,083,788) - 2,160,664
----- End of picture text -----

The narrative explaining the purpose of each fund is given at the foot of the note below.

43

Notes to the financial statements

Company registration number: 06648679

For the year ended 31 December 2024

==> picture [507 x 207] intentionally omitted <==

----- Start of picture text -----
18b Movements in funds (prior year)
At 1 January Income & Expenditure At 1st January
2023 gains & losses Transfers 2024
£ £ £ £ £
Restricted funds:
The Gates Foundation 413,527 2,525,441 (2,470,710) - 468,258
All-party parliamentary group 76,983 45,000 (48,891) - 73,093
GlaxoSmithKline plc - 85,000 (85,000) - -
Medicines for Malaria Venture - 58,768 (58,768) - -
Open Philanthropy - 1,357,000 (935,777) - 421,223
RES Africa 293,087 - (225,215) - 67,871
RES Summit 77,188 - (77,188) - -
Total restricted funds 860,785 4,071,209 (3,901,549) - 1,030,445
Unrestricted funds:
General funds 1,146,104 664,494 (878,612) - 931,986
Total funds 2,206,889 4,735,703 (4,780,161) - 1,962,431
----- End of picture text -----

Designated reserves

The Trustees’ policy, updated in November 2022, is to maintain two reserves, together shown on the balance sheet as unrestricted funds: one, equivalent to the value of four months' core operating costs (The Resilience Reserve), and two, reserves allocated to specific future projects to be delivered within 24 months ( The Designated Reserves ).

Purposes of restricted funds

The Gates Foundation

MNM UK receives funding from the The Gates Foundation directly from the Foundation. This funding covers a wide range of organisational activities including supporting the charity's campaigns and advocacy work in the UK and beyond.

The funds transferred to unrestricted funds represents an agreed contribution towards indirect costs agreed by the funder.

All-Party Parliamentary Group

MNM UK hosts the All-party parliamentary group on Malaria and NTDs and receives funding from The Leprosy Mission, on behalf of the UK Coalition Against NTDs, Medicines for Malaria Venture, Path MVI, Sightsavers - Uniting to Combat NTDs, and Drugs for Neglected Diseases initiative (DNDi). This funding supports the charity's advocacy work in the UK and beyond.

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) funded MNMUK's activities in the UK including supporting the charity's campaigns and advocacy work.

Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) donated funds to support MNMUK's UK and global advocacy and communications work.

Open Philanthropy

MNM UK received a two-year grant from Open Philanthropy to support advocacy and campaigns for donor and Commonwealth malaria funding.

The funds transferred to unrestricted funds represents an agreed contribution towards indirect costs agreed by the funder.

RES Africa

MNMUK received funding from Motsepe Foundation and long-term supporters Fever-Tree to support the organisation's continued delivery of Africa focused advocacy and communications work.

RES Summit

MNMUK received funding from RBM Partnership to End Malaria, New Venture Fund and several sector partneers to support the delivery of the Kigali Malaria and NTD Summit and associated communications work in 2022.

19 Operating lease commitments payable as a lessee

e year
o and fve years
ead ofce is leased until 31 January 2025. The cost of this is shown below:		 2024
£
6,908
-		 2023
£
165,802
13,817
6,908 179,619

44

MALARIANOMORE.ORG.UK

@MALARIANOMOREUK

COMPANY NUMBER 06648679

CHARITY NUMBER 1126222

REGISTERED IN ENGLAND AND WALES

85 GREAT PORTLAND STREET, FIRST FLOOR, LONDON, W1W 7LT

==> picture [36 x 188] intentionally omitted <==

Independent auditors’ report

Opinion

We have audited the financial statements of Malaria No More United Kingdom (the ‘parent charitable company’) and its subsidiaries (the ‘group’) for the year ended 31 December 2024 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the group financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions related to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Malaria No More United Kingdom’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

29

Other information

The other information comprises the information included in the trustees’ annual report other than the group financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the group financial statements does not cover the other information, and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the group financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the group financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Act 2011 requires us to report to you if, in our opinion:

30

==> picture [36 x 188] intentionally omitted <==

Responsibility of Trustees

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors’ responsibilities for the audit of financial statements

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charites Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

Capability of the audit in detecting irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

31

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Jonathan Orchard (Senior statutory auditor)

for and on behalf of Sayer Vincent LLP, Statutory Auditor 110 Golden Lane, LONDON, EC1Y 0TG

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006

32